Teladoc Health Reports Fourth-Quarter and Full-Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Teladoc (TDOC) Tops Q4 EPS by 7c, Revenues Beat; Offers Q1 & FY20 Revenue Guidance Above Consensus
February 26, 2020 4:05 PM ESTTeladoc (NYSE: TDOC) reported Q4 EPS of ($0.26), $0.07 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $156.49 million versus the consensus estimate of $152.95 million.
We demonstrated outstanding performance in the fourth quarter and full year of 2019 as we reported record results that were at the high end or exceeded our expectations on all key metrics. Our diversified growth strategies are driving strong growth across our channels, said Jason Gorevic, chief executive officer. Looking forward, we are... More
